BACKGROUND: Anal cancer is caused by human papillomavirus (HPV). Moreover, human immunodeficiency virus (HIV) is an additional risk factor for anal cancer. Therefore, when designing preventive protocols for HIV-infected men, it is important to detect high-risk (HR) oncogenic HPV genotypes present in their anal canals. However, most studies have focused only on men who have sex with men (MSM). OBJECTIVE: To estimate the prevalence of HPV and describe its genotype distribution using anal cytology and histology specimens from HIV-infected populations of MSM and men who have sex with women (MSW). DESIGN: Crosssectional study of the CARH·MEN cohort. SETTING: Single-center prospective cohort of HIV-infected men attending the Outpatient HIV Clinic of Hospital Germans Trias i Pujol (Spain), where they undergo annual screening for HPV infection of the anus, penis and mouth. PATIENTS: Four hundred eighty-three HIV-infected men (341 MSM, 142 MSW) with no current or previous history of anal condylomata. MAIN OUTCOME MEASURES: HPV genotypes detected (multiplex-PCR), cytology results (Papanicolaou test) and histology results (biopsy-based). RESULTS: Cytological abnormalities were detected in 40% of MSM (129/321; 95%CI, 35-46) and 20% of MSW (26/131; 95%CI, 13-28) (OR=2.7; 95%CI, 1.7-4.4). All high-grade squamous intraepithelial lesions (HSIL) were positive for HR-HPV in both groups. High-resolution anoscopy was performed in 146 patients (120 MSM, 26 MSW) with abnormal cytological diagnoses. Lesions were visualized in 80 MSM (67%) and 14 MSW (54%) (OR=1.7 [95%CI, 0.7-4.0]). Histological diagnosis was anal intraepithelial neoplasia (AIN)-1 in 51 MSM (64%) and 6 MSW (43%), AIN-2 in 9 MSM (11%) and 3 MSW (21%), AIN-3 in 7 MSM (9%) and 1 MSW (7%), and normal in 13 MSM (16%) and 4 MSW (29%). HPV16 was the most prevalent HR genotype. LIMITATIONS: Study limitations include its crosssectional design. CONCLUSIONS: Anal cancer screening should be offered to all HIV-infected men, regardless of their sexual orientation.
BACKGROUND:Anal cancer is caused by human papillomavirus (HPV). Moreover, human immunodeficiency virus (HIV) is an additional risk factor for anal cancer. Therefore, when designing preventive protocols for HIV-infectedmen, it is important to detect high-risk (HR) oncogenic HPV genotypes present in their anal canals. However, most studies have focused only on men who have sex with men (MSM). OBJECTIVE: To estimate the prevalence of HPV and describe its genotype distribution using anal cytology and histology specimens from HIV-infected populations of MSM and men who have sex with women (MSW). DESIGN: Crosssectional study of the CARH·MEN cohort. SETTING: Single-center prospective cohort of HIV-infectedmen attending the OutpatientHIV Clinic of Hospital Germans Trias i Pujol (Spain), where they undergo annual screening for HPV infection of the anus, penis and mouth. PATIENTS: Four hundred eighty-three HIV-infectedmen (341 MSM, 142 MSW) with no current or previous history of anal condylomata. MAIN OUTCOME MEASURES: HPV genotypes detected (multiplex-PCR), cytology results (Papanicolaou test) and histology results (biopsy-based). RESULTS: Cytological abnormalities were detected in 40% of MSM (129/321; 95%CI, 35-46) and 20% of MSW (26/131; 95%CI, 13-28) (OR=2.7; 95%CI, 1.7-4.4). All high-grade squamous intraepithelial lesions (HSIL) were positive for HR-HPV in both groups. High-resolution anoscopy was performed in 146 patients (120 MSM, 26 MSW) with abnormal cytological diagnoses. Lesions were visualized in 80 MSM (67%) and 14 MSW (54%) (OR=1.7 [95%CI, 0.7-4.0]). Histological diagnosis was anal intraepithelial neoplasia (AIN)-1 in 51 MSM (64%) and 6 MSW (43%), AIN-2 in 9 MSM (11%) and 3 MSW (21%), AIN-3 in 7 MSM (9%) and 1 MSW (7%), and normal in 13 MSM (16%) and 4 MSW (29%). HPV16 was the most prevalent HR genotype. LIMITATIONS: Study limitations include its crosssectional design. CONCLUSIONS:Anal cancer screening should be offered to all HIV-infectedmen, regardless of their sexual orientation.
Authors: Maarten F Schim van der Loeff; Sofie H Mooij; Oliver Richel; Henry J C de Vries; Jan M Prins Journal: Curr HIV/AIDS Rep Date: 2014-09 Impact factor: 5.071
Authors: Lois J Conley; Timothy J Bush; Teresa M Darragh; Joel M Palefsky; Elizabeth R Unger; Pragna Patel; Martin Steinau; E Milu Kojic; Harold Martin; E Turner Overton; Susan Cu-Uvin; John Hammer; Keith Henry; Kathleen Wood; John T Brooks Journal: J Infect Dis Date: 2015-08-12 Impact factor: 5.226
Authors: Carmen Hidalgo-Tenorio; Mar Rivero-Rodriguez; Concepción Gil-Anguita; Javier Esquivias; Rodrigo López-Castro; Jessica Ramírez-Taboada; Mercedes López de Hierro; Miguel A López-Ruiz; R Javier Martínez; Juan P Llaño Journal: PLoS One Date: 2015-04-07 Impact factor: 3.240
Authors: Carmen Hidalgo-Tenorio; Mar Rivero-Rodriguez; Concepción Gil-Anguita; Mercedes Lopez De Hierro; Pablo Palma; Jessica Ramírez-Taboada; Javier Esquivias; Miguel Angel López-Ruz; Rosario Javier-Martínez; Juan Pasquau-Liaño Journal: PLoS One Date: 2014-03-27 Impact factor: 3.240
Authors: Ilia Beliakov; Maria Senina; Yuriy Tyulenev; Elena Novoselova; Viktor Surovtsev; Alexander Guschin Journal: Can J Infect Dis Med Microbiol Date: 2021-05-31 Impact factor: 2.471
Authors: Chang Hun Lee; Sun Hee Lee; Shinwon Lee; Heerim Cho; Kye-Hyung Kim; Jung Eun Lee; Eun Ju Jung; Su Jin Lee; Eun Jung Kim; Ki Hyung Kim; Eunsoo Moon; Hong Je Cho Journal: PLoS One Date: 2016-08-22 Impact factor: 3.240